<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04287647</url>
  </required_header>
  <id_info>
    <org_study_id>STU00209539</org_study_id>
    <nct_id>NCT04287647</nct_id>
  </id_info>
  <brief_title>Transpyloric Stenting as a Predictor for G-POEM for Refractory Gastroparesis</brief_title>
  <official_title>Transpyloric Stenting for Refractory Gastroparesis Prior to Gastric Per-Oral Endoscopic Myotomy: A Prospective Sham Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective sham study to investigate the role of transpyloric stenting with lumen&#xD;
      apposing metal stent (LAMS) as a predictor for clinical response to gastric per-oral&#xD;
      endoscopic pyloromyotomy (GPOEM) for refractory gastroparesis. The study hypothesizes that&#xD;
      clinical improvement with transpyloric stenting in patients with refractory gastroparesis is&#xD;
      a predictor of subsequent clinical success of GPOEM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroparesis is defined as a complex syndrome of symptoms including early satiety,&#xD;
      post-prandial fullness, nausea, vomiting, bloating, and upper abdominal pain with a&#xD;
      corresponding objective delay in gastric emptying in the absence of mechanical obstruction.&#xD;
      Recent epidemiologic data has shown a substantial increase of 158% in hospitalizations&#xD;
      related to gastroparesis in recent years. The pathogenesis underlying gastroparesis is&#xD;
      complex with multiple potential underlying mechanisms including impaired gastric&#xD;
      accommodation, autonomic neuropathy, vagal nerve injury, uncoordinated gastric contractility,&#xD;
      and pyloric dysfunction.&#xD;
&#xD;
      Effective and durable medical treatment of gastroparesis has remained clinically challenging.&#xD;
      Currently metoclopramide is the only medication approved by the U.S. Food and Drug&#xD;
      Administration (FDA) for diabetic gastroparesis, and treatment courses are recommended to be&#xD;
      limited to a maximum of 12 weeks due to the risk of the irreversible side effect of tardive&#xD;
      dyskinesia. Surgical treatments for gastroparesis also remain limited, with sparse existing&#xD;
      data to support the use of implanted gastric electrical stimulation for treatment of&#xD;
      refractory gastroparesis, which is currently approved by the FDA only for compassionate use.&#xD;
      More recently, surgical pyloroplasty has been examined in treatment of gastroparesis, which&#xD;
      has long been recognized as a technique to improve gastric drainage for mechanical&#xD;
      obstructions and during elective vagotomy after gastric surgery. A recent study examined&#xD;
      surgical pyloroplasty in 28 patients with post-surgical gastroparesis with 83% patients&#xD;
      reporting significant clinical improvement at one-month follow-up but current surgical&#xD;
      literature remains limited in this area and has focused primarily on post-surgical&#xD;
      gastroparesis.&#xD;
&#xD;
      Given the lack of effective treatment options, endoscopic therapies for gastroparesis have&#xD;
      recently been investigated as adjunctive or alternative methods to treat gastroparesis.&#xD;
      Pyloric dysfunction characterized by pyloric restriction or pylorospasm with prolonged&#xD;
      periods of increased pyloric tone and contractions has been brought to attention as an area&#xD;
      of targetable therapy for a subset of patients with gastroparesis. Pyloric botulinum toxin&#xD;
      injections initially demonstrated improvement in gastric emptying after treatment, but&#xD;
      subsequent results from double-blinded placebo-control studies failed to demonstrate a&#xD;
      difference in symptoms compared to placebo.&#xD;
&#xD;
      Transpyloric stenting was initially reported in 2013 in three cases of refractory&#xD;
      gastroparesis with placement of a double layered, fully-covered, Niti-S self-expandable metal&#xD;
      stent (TaeWoong Medical) across the pylorus with improvement in gastric emptying and symptoms&#xD;
      in all three patients. A subsequent study of 30 patients with refractory gastroparesis who&#xD;
      underwent transpyloric stenting demonstrated high technical success of stent placement (98%)&#xD;
      with improvement of clinical symptoms in 75% of patients and 4-hour gastric emptying studies&#xD;
      in 69% of patients. Stent migration was found to occur in 59% of patients without any&#xD;
      associated adverse events. Current focus on transpyloric stenting in gastroparesis centers&#xD;
      around determining optimal stent type and method of stent anchorage as well as the role of&#xD;
      transpyloric stenting in treatment given lack of long-term durability.&#xD;
&#xD;
      With advancements in endoscopic submucosal dissection, G-POEM has recently come in to light&#xD;
      as a minimally invasive technique to treat refractory gastroparesis. Esophageal endoscopic&#xD;
      myotomy has previously been well-described as a procedure for treatment of achalasia, and&#xD;
      this technique was adopted by in 2013 with the first G-POEM for refractory gastroparesis. A&#xD;
      subsequent multicenter study in 2017 reported on 30 patients with refractory gastroparesis&#xD;
      who underwent G-POEM with a technical success rate of 100%. At 5.5-month follow-up, 86% of&#xD;
      patients were found to have clinical response. Repeat gastric emptying studies after G-POEM&#xD;
      also normalized or improved in 47% and 37% of patients respectively. G-POEM has now gained&#xD;
      both national and international recognition in succeeding studies as a feasible and safe&#xD;
      technique to effectively treat refractory gastroparesis in a subset of patients.&#xD;
&#xD;
      Identifying predictors of success of G-POEM for treatment of gastroparesis is essential in&#xD;
      further recognizing appropriate patients who would benefit from this therapy. As transpyloric&#xD;
      stenting and G-POEM share underlying mechanisms of disruption of the pylorus, the&#xD;
      investigators propose that improvement with transpyloric stenting in patients with refractory&#xD;
      gastroparesis can be a predictor of subsequent response with G-POEM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">January 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 6, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Participants and other care providers are blinded to whether they receive a transpyloric stent vs sham</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response will be assessed by the gastroparesis cardinal symptom index (GCSI) scores</measure>
    <time_frame>1-2 years</time_frame>
    <description>GCSI assessment is based off an average of 16 questions that are scored from 0-5, with higher scores indicating a worse clinical outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Age</measure>
    <time_frame>1-2 years</time_frame>
    <description>Assessed in years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>1-2 years</time_frame>
    <description>Assessed in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>1-2 years</time_frame>
    <description>Assessed in inches</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>1-2 years</time_frame>
    <description>Assessed in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1-2 years</time_frame>
    <description>Assessed based on current American Society for Gastrointestinal Endoscopy (ASGE) guideline definitions for endoscopic adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure length</measure>
    <time_frame>intraoperative</time_frame>
    <description>Assessed in minutes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Transpyloric stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this group, patient's will be randomized to receive a transpyloric stent for treatment of refractory gastroparesis. They will be blinded for one month after stent placement as to whether they received a stent or sham.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>In this group, patient's will be randomized to sham for treatment of refractory gastroparesis. They will be blinded for one month after stent placement as to whether they received a stent or sham.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transpyloric stent</intervention_name>
    <description>See arm/group descriptions</description>
    <arm_group_label>Transpyloric stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients greater than 18 years of age with gastroparesis refractory to standard&#xD;
             medical therapy (lifestyle and diet modifications, prokinetics) or contraindication to&#xD;
             standard therapies (e.g. allergies to prokinetic agents)&#xD;
&#xD;
          -  Patients with diabetic, idiopathic or post-surgical gastroparesis&#xD;
&#xD;
          -  Patients with confirmed diagnosis of gastroparesis via gastric emptying study&#xD;
             (abnormal gastric emptying will be defined as â‰¥10 % residual activity at 4 h on a&#xD;
             standardized nuclear medicine TC-99 m sulfur colloid solid-phase gastric emptying&#xD;
             study)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with prior history of gastroenteric anastomosis or any GI surgeries with&#xD;
             pyloric involvement&#xD;
&#xD;
          -  Patients with gastroesophageal malignancy&#xD;
&#xD;
          -  Patients who are unable to tolerate upper endoscopy secondary to cardiopulmonary&#xD;
             instability or other contraindications to endoscopy&#xD;
&#xD;
          -  Patients with cirrhosis&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding&#xD;
&#xD;
          -  Patients with uncorrectable coagulopathy defined by INR &gt;1.5 or platelets &lt;50&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>A. Aziz Aadam, MD</last_name>
    <phone>2244060582</phone>
    <email>abdul.aadam@northwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kevin Liu, MD</last_name>
    <phone>6233639052</phone>
    <email>kevin-liu@northwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Aziz Aadam, MD</last_name>
      <phone>224-406-0582</phone>
      <email>abdul.aadam@northwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>A. Aziz Aadam</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

